Recent Innovations in the Management of Low-Grade Gliomas
- 14 July 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Current Treatment Options in Neurology
- Vol. 14 (4), 369-380
- https://doi.org/10.1007/s11940-012-0185-6
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- Detection of 1p19q Deletion by Real-Time Comparative Quantitative PCRBiomarker Insights, 2012
- Immunotherapy for gliomaCurrent Opinion in Neurology, 2011
- Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomasJournal of Experimental & Clinical Cancer Research, 2011
- Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomideNeuro-Oncology, 2010
- Seizures in Patients Undergoing Resection of Low-Grade GliomasEpilepsy Currents, 2009
- Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131Neuro-Oncology, 2009
- IDH1andIDH2Mutations in GliomasThe New England Journal of Medicine, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004